隨著數位技術的快速發展，數位轉型已成為醫藥產業應對全球健康需求變遷與市場競爭壓力的重要策略。本研究探討Ａ藥廠如何透過數位轉型推動利害關係人並驅動價值共創，深入剖析數位技術在企業內部運營及外部協作中的應用。
本研究採用質性研究方法，透過訪談Ａ國際製藥公司及醫療機構的關鍵利益相關者，分析數位轉型過程中的技術革新、組織變革與協作機制。結果顯示，數位轉型主要透過三大層面產生影響：第一，數位技術（如大數據分析、人工智慧及數位平台）的應用，提升Ａ藥廠內部流程效率及數據驅動決策能力；第二，數位行銷與遠程醫療技術促進藥廠與醫療專業人員的互動，形成更即時且精準的資訊傳遞；第三，跨部門及跨組織之間的數位協作，促成價值共創的生態系統，實現以患者為中心的服務創新。
本研究發現，數位轉型不僅是技術的應用，更是一場企業文化與組織結構的全面變革，A藥廠須透過數位工具有效整合內外部資源，並與利益相關者協同合作，共同創造新的價值。此研究成果可為醫藥產業提供數位轉型策略參考，並為未來價值共創模式的設計提供理論支持。

Digital transformation has become a cornerstone strategy for the pharmaceutical industry, enabling firms to address evolving global healthcare demands and intensifying market competition. It extends beyond technological innovation, representing a comprehensive reconfiguration of business processes, organizational culture, and stakeholder relationships. This study investigates how Firm A leverages digital transformation to drive value co-creation through innovative applications across internal operations and external collaborations. By adopting advanced technologies such as big data analytics, artificial intelligence (AI), and digital platforms, Firm A has achieved significant improvements in operational efficiency, decision-making, and resource allocation. For example, AI-powered tools in clinical trials have reduced timelines, increased accuracy, and optimized resource utilization, enabling faster innovation and enhanced therapeutic strategies. Moreover, these tools allow Firm A to analyze complex datasets more effectively, identifying patterns that inform the development of precision medicine. Additionally, digital platforms have transformed supply chain management by enabling real-time tracking, optimizing logistics, and minimizing delays, ensuring that medications reach patients more efficiently. These advancements underscore the transformative potential of digital technologies in reshaping traditional pharmaceutical operations, positioning Firm A to meet the complexities of global healthcare systems effectively.
Beyond internal efficiencies, digital transformation has revolutionized Firm A’s engagement with external stakeholders, particularly healthcare professionals (HCPs), regulatory bodies, and technology providers. Digital marketing platforms allow Firm A to deliver timely, accurate, and personalized information to HCPs, fostering trust, strengthening collaboration, and enhancing professional relationships. These platforms ensure that medical professionals have access to the latest clinical and product-related data, supporting informed decision-making and ultimately improving patient outcomes. Similarly, telemedicine technologies have expanded Firm A’s capacity to provide real-time communication and remote support, creating a dynamic and responsive interaction framework. This capability is particularly impactful in underserved regions, where access to healthcare resources is limited. Furthermore, Firm A has established a robust value co-creation ecosystem by integrating shared data systems and collaborative platforms across internal departments and external partnerships. Collaborations with research institutions, technology developers, and regulatory agencies have driven patient-centered innovations, including personalized medicine, precision healthcare solutions, and tailored treatment plans. These initiatives not only address diverse patient needs but also position Firm A as a global leader in advancing medical innovation. Additionally, Firm A’s digital initiatives enhance transparency in regulatory processes, facilitating faster compliance and accelerating patient access to life-saving therapies. By simplifying complex regulatory workflows, Firm A ensures its innovations reach the market more efficiently, benefitting both patients and healthcare systems.
The findings of this study emphasize that digital transformation requires a holistic shift in organizational structure, culture, and collaboration strategies. For Firm A, achieving success in this transformative journey involves addressing challenges such as data privacy, regulatory compliance, and gaps in digital literacy among employees and stakeholders. Robust cybersecurity frameworks are critical for safeguarding sensitive information and maintaining compliance with international regulatory standards. These measures help build trust within the ecosystem and ensure seamless operations across diverse markets. Moreover, Firm A has invested heavily in comprehensive digital training programs designed to equip its workforce with the skills needed to leverage advanced technologies effectively. These programs foster adaptability and a culture of continuous learning, enabling the organization to respond proactively to emerging trends and challenges. Predictive analytics further empower Firm A to anticipate market demands, optimize resource deployment, and align strategies with dynamic healthcare needs. Beyond internal training, Firm A collaborates with educational institutions to promote digital literacy among external stakeholders, ensuring that healthcare providers and patients can effectively utilize digital tools. By addressing these structural and cultural barriers, Firm A exemplifies how organizations can achieve resilience and leadership in a rapidly changing pharmaceutical industry.
Lastly, this study highlights the importance of adopting a patient-centric approach to digital transformation, where technology is utilized not only to enhance efficiency but also to improve patient outcomes and experiences. Firm A’s innovations in remote monitoring systems, telehealth solutions, and personalized care plans demonstrate how digital tools can facilitate holistic patient care, focusing on improving treatment outcomes and quality of life. These tools empower patients to take a more active role in managing their health by providing them with access to critical information and self-care resources. Furthermore, digital platforms enable Firm A to engage directly with patients, fostering trust through transparent communication and personalized support. This strategy aligns with global trends toward value-based healthcare, emphasizing patient outcomes over traditional volume-based models. By integrating advanced technologies with cultural and structural changes, Firm A enhances its value proposition and contributes to the broader evolution of global healthcare systems. Additionally, Firm A utilizes patient feedback collected through digital tools to refine its strategies, ensuring its solutions remain aligned with real-world needs. This patient-focused strategy not only solidifies Firm A’s leadership in digital transformation but also provides a blueprint for other pharmaceutical companies navigating similar complexities. Ultimately, Firm A’s efforts highlight the critical role of balancing innovation with adaptability, ensuring sustainable success in a rapidly digitizing healthcare ecosystem.

一、中文文獻
方世杰、李慶芳（2016）。價值共創的本質問題探討。管理評論，28 (4)，15–23。
杜鵬、張偉、李慧、王楠（2017）。價值共創的概念框架與實踐。管理科學學報，30 (2)，45–57。
鐘志明 （2019）。互動在價值共創中的重要性研究。管理學報，36 (3)，67–78。
二、英文文獻
Alami, H., Gagnon, M. P., & Fortin, J. P. (2017). Digital health and the challenge of health systems transformation. Mhealth, 3.
Al-Rahbi, A. S., Khan, M. M., & Al-Balushi, H. S. (2017). Contributions of medieval Arab medicine to pharmacology. Journal of Medical History, 23(4), 251–264.
Berman, S. J. (2012). Digital transformation: Opportunities to create new business models. Strategy & Leadership, 40(2), 16–24.
Beta. (2024). Podcast-Folge 3: TEST | PS | Die Zukunft des Gesundheitswesens https://www.welt.de/beta/article252897092/Podcast-Folge-3-TEST-PS-Die-Zukunft-des-Gesundheitswesens.html?utm_source=chatgpt.com
Bharadwaj, A., El Sawy, O. A., Pavlou, P. A., & Venkatraman, N. (2013). Digital business strategy: Toward a next generation of insights. MIS Quarterly, 37(2), 471–482.
Braun, V., & Clarke, V. (2006). Using thematic analysis in psychology. Qualitative Research in Psychology, 3(2), 77–101.
Brenner, D. (2018). Modern medicine: The intersection of biology, chemistry, and innovation. Oxford University Press.
Chen, C. M. (2023). The application of digital detailing and telehealth tools in post-pandemic pharmaceutical marketing. Pharmaceutical Marketing Review, 14(2), 101–116.
Chen, M. (2021). The role of digital platforms in value co-creation: A case study. Journal of Business Innovation, 14(2), 98–112.
Chen, Y. J. (2023). Value co-creation strategies in pharmaceutical companies. Journal of Business Strategy, 22(1), 56–68.
Chen, Y., Zhang, W., & Wang, Q. (2021). Digital transformation and value co-creation in the pharmaceutical sector: A case study perspective. Health Industry Management Review, 12(4), 78–92.
Chesbrough, H. W. (2003). Open innovation: The new imperative for creating and profiting from technology. Harvard Business School.
Creswell, J. W. (2013). Qualitative inquiry and research design: Choosing among five approaches (3rd ed.). SAGE Publications.
Deloitte. (2020). The digital transformation of business: The new path to business value.
Deloitte. (2021). The future of the life sciences industry: Trends in digital transformation. Deloitte Insights.
Deloitte. (2023). Pharma and life sciences predictions 2023: Trends and priorities. Deloitte Insights.
Elkington, J. (1997). Cannibals with forks: The triple bottom line of 21st century business. Capstone.
Freeman, R. E. (1984). Strategic management: A stakeholder approach. Pitman.
Gebayew, C., Hardini, I. R., Abazi, D., & Salanova, D. (2018). The impact of digital transformation on firm performance. European Journal of Business and Social Sciences, 7(5), 27–38.
Gillis, M. (2021). Biopharma Can Reduce the Cost of Bringing A Treatment to Market by More Than US$1 Billion, According to Accenture Report https://newsroom.accenture.com/news/2021/biopharma-can-reduce-the-cost-of-bringing-a-treatment-to-market-by-more-than-us-1-billion-according-to-accenture-report
Grönroos, C., & Voima, P. (2013). Critical service logic: Making sense of value creation and co-creation. Journal of the Academy of Marketing Science, 41(2), 133–150.
https://www.marketwatch.com/story/pfizer-follows-eli-lillys-lead-in-direct-to-consumer-push-e7a75f92?utm_source=chatgpt.com
Huang, X. (2015). The development of ancient medical practices. Academic Press.
Kane, G. C., Palmer, D., Phillips, A. N., & Kiron, D. (2015). Is your business ready for digital transformation? MIT Sloan Management Review.
Keller, K. L. (2013). Strategic Brand Management: Building Measuring, and Managing Brand Equity, Global Edition (4th ed.). Pearson Education.
Kotler, P., & Keller, K. L. (2016). Marketing management (15th ed.). Pearson Education.
KPMG. (2021). Pharmaceutical digital transformation: Trends and challenges.
Kumar, V., & Pansari, A. (2016). The construct, measurement, and impact of employee engagement: A marketing perspective. Customer Needs and Solutions, 3(1), 52–67.
Kumar, V., & Ramachandran, D. (2021). Digital platforms and stakeholder collaboration for value co-creation. Journal of Business Research, 124, 31–39.
Laise, E. (2003). Pfizer follows Eli Lilly’s lead in direct-to-consumer push
Lee, I., & Shin, Y. J. (2020). How digital transformation impacts business models and customer experiences. Journal of Service Science Research, 12(1), 3–12.
Lepak, D. P., Smith, K. G., & Taylor, M. S. (2007). Value creation and value capture: A multilevel perspective. Academy of Management Review, 32(1), 180–194.
Li, M. Z. (2023). Digital transformation and interaction between pharmaceutical firms and healthcare professionals. Journal of Healthcare Strategy, 21(3), 78–90.
Lin, M. L. (2023). Digital tools as core competitive advantages in the healthcare industry. Taiwan Healthcare Review, 11(4), 123–137.
Liu, S., & Xie, J. (2021). The integration of big data analytics and cloud computing in digital transformation. Technological Forecasting and Social Change, 171, 120927.
Lusch, R. F., & Vargo, S. L. (2014). The service-dominant logic of marketing: Dialog, debate, and directions. Routledge.
Marr, B. (2017). Data strategy: How to profit from a world of big data, analytics and the internet of things. Kogan Page Publishers.
Matt, C., Hess, T., & Benlian, A. (2015). Digital transformation strategies. Business & Information Systems Engineering, 57(5), 339–343.
McGowan, R. A., Boulton, W. R., & Hutton, R. (2021). Digital transformation and organizational change: A review and research agenda. Journal of Business Research, 124, 604–617.
McKinsey. (2017). The analytics revolution: How companies are using data to become more agile and effective. McKinsey & Company.
McKinsey. (2020). The future of value creation in the digital age. McKinsey & Company.
McKinsey. (2022). Artificial intelligence in drug discovery: The game changer. McKinsey & Company.
Meyer, J. (2019). Commercialization and globalization of the pharmaceutical industry. Pharmaceutical Business Review, 12(3), 45–60.
Nature Medicine. (2020). Artificial intelligence in drug development and healthcare. Nature Medicine.
Novartis AG. (2022). Creating value in the evolving healthcare ecosystem. Novartis AG.
Parviainen, P., Kääriäinen, J., Tihinen, M., & Teppola, S. (2017). Tackling the digitalization challenge: How to benefit from digitalization in practice. International Journal of Information Systems and Project Management, 5(1), 63–77.
Pfizer Inc. (2022). Annual report 2022: Advancing breakthroughs that change patients’ lives. Pfizer Inc.
Porter, M. E., & Kramer, M. R. (2018). Creating shared value: How to reinvent capitalism—And unleash a wave of innovation and growth. In Managing sustainable business: An executive education case and textbook (pp. 323-346). Dordrecht: Springer Netherlands.
Prahalad, C. K., & Ramaswamy, V. (2004). Co-creation experiences: The next practice in value creation. Journal of Interactive Marketing, 18(3), 5–14.
Ramaswamy, V., & Gouillart, F. J. (2010). The power of co-creation: Build it with them to boost growth, productivity, and profits. Free Press.
Schallmo, D., & Williams, C. A. (2018). Digital transformation now!. Springer International Publishing.
Schwertner, K. (2017). Digital transformation of business. Trakia Journal of Sciences, 15(Suppl. 1), 388–393.
Smith, A., Jones, T., & Lee, M. (2020). Emerging digital transformation trends in healthcare: Implications for pharmaceutical innovation. Healthcare Technology Journal, 19(4), 233–250.
Tallon, P. P., Queiroz, M., Coltman, T., & Sharma, R. (2019). Digital innovation and transformation: An introduction to the special issue. Information Systems Journal, 29(1), 1–8.
Vargo, S. L., & Lusch, R. F. (2004). Evolving to a new dominant logic for marketing. Journal of Marketing, 68(1), 1–17.
Vargo, S. L., & Lusch, R. F. (2016). Institutions and axioms: An extension and update of service-dominant logic. Journal of the Academy of Marketing Science, 44(1), 5–23.
Vial, G. (2019). Understanding digital transformation: A review and a research agenda. The Journal of Strategic Information Systems, 28(2), 118–144.
Wang, J. M. (2022). Application of AI and big data in Taiwan's pharmaceutical industry. Taiwan Journal of Innovation Management, 8(1), 45–58.
Westerman, G., Bonnet, D., & McAfee, A. (2014). Leading digital: Turning technology into business transformation. Harvard Business Press.
Yin, R. K. (2003). Case study research: Design and methods (3rd ed.). SAGE Publications.
Yin, R. K. (2018). Case study research and applications: Design and methods (6th ed.). SAGE Publications.